NCT00094718View on ClinicalTrials.gov

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
West Nile Fever Encephalitis
Interventions
BIOLOGICAL

WN/DEN4-3'delta30

Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)

BIOLOGICAL

Placebo

Placebo for WN/DEN4-3'delta30 vaccine

Trial Locations (2)

21205

Johns Hopkins School of Public Health, Baltimore

37232

Vanderbilt University School of Medicine, Nashville

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00094718 - Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults | Biotech Hunter | Biotech Hunter